# **Special Issue**

# The Challenges and Therapeutic Prospects in Eye Disease

## Message from the Guest Editor

In the last decade we have gained a deeper understanding of the underlying pathogenesis of various ocular disease, which has resulted in the development of novel effective targeted therapies such as teprotumumab for the treatment of active thyroid eye disease. This Special Issues of *Journal of Personalized Medicine* aims to update the current evidence and collect the latest findings on various ocular disease. Particular attention will be paid to original research articles, case reports, and state-of-the-art reviews to explore how to *overcome* the *challenges* and navigate the emerging therapeutic landscape.

### **Guest Editor**

Dr. Tsai Chieh-Chih

- 1. Department of Ophthalmology, Taipei Veterans General Hospital, Taipei, Taiwan
- 2. School of Medicine, National Yang Ming Chiao Tung University, Hsinchu, Taiwan

## Deadline for manuscript submissions

closed (25 April 2023)



# Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



## mdpi.com/si/104563

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/

jpm





# Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



# About the Journal

# Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on "omics"-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical

subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

### Editor-in-Chief

### Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2. Canada

### **Author Benefits**

## **High Visibility:**

indexed within Scopus, PubMed, PMC, Embase, and other databases.

### Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

## **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

